- Previously received at least one line of prior systemic therapy for metastatic disease; if the patient has a sensitizing EGFR mutation or ALK rearrangement, the patient must have received at least one prior targeted therapy for metastatic disease (ie, EGFR tyrosine kinase inhibitor [TKI] therapy or ALK TKI therapy, respectively); there is no limit on prior therapies allowed; patients must have completed previous treatment (including other investigational therapy) in greater than or equal to the following times prior to initiation of trial treatment: